PubMed Health⌕ Search

PubMed · 6108713

Ulcerative colitis and its treatment.

Abstract

Ulcerative colitis and its epidemiology, etiology, pathophysiology, diagnosis, clinical findings, complications, treatment, and prognosis are reviewed. Ulcerative colitis, an inflammatory disease of unknown origin that varies in severity and clinical course, occurs most often in patients 30 to 70 years old. It appears to have a genetic component and to involve the immunological system. The cardinal symptom is usually bloody diarrhea, and the disease may be classified by either the severity of an attack, the clinical course, or by anatomic localization of inflammation. Initial treatment of ulcerative colitis generally includes corticosteroids administered either rectally, orally, or parenterally. Oral sulfasalazine has been found useful in treating this condition and is often used for prolonged therapy to prevent relapses. Azathioprine, cromolyn sodium, antidiarrheal/anticholinergic agents, and nutritional supplements are used at times. Surgery is indicated under certain conditions and usually involves panproctocolectomy with permanent ileostomy. The prognosis of ulcerative colitis depends upon the age of the patient, the extent of colonic involvement, and the severity of the attach.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A I Jacknowitz. 1980. Ulcerative colitis and its treatment.. https://pubmed.ncbi.nlm.nih.gov/6108713/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗